Prospectus | Jotup

NEXT BRIDGE HYDROCARBONS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Next Bridge Hydrocarbons, Inc., a spin-off from Meta Materials, Inc. (OTC PINK: MMTLP), Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsu

Retrieved on:

Wednesday, April 3, 2024

NBH, Metamaterial, Orogrande Basin, Sale, Disclosure, Prospectus, Complaint, OTC, Court, Register, Person, Security (finance)

NBH dates back several years to an earlier company named Torchlight Energy Resources, Inc. (“Torchlight”).

Key Points:

NBH dates back several years to an earlier company named Torchlight Energy Resources, Inc. (“Torchlight”).
Torchlight was an oil and gas company that operated primarily in the Orogrande Basin in West Texas under the control of Defendant Gregory McCabe.
In connection with the merger, legacy Torchlight shareholders received shares of non-voting Meta Materials preferred stock (the “Preferred Stock”).
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

DIGITAL ALLY, INC ANNOUNCES 2023 OPERATING RESULTS

Retrieved on:

Tuesday, April 2, 2024

LENEXA, Kansas, April 02, 2024 (GLOBE NEWSWIRE) -- Digital Ally, Inc. (Nasdaq: DGLY) (the “Company” or “our”), today announced its operating results for fiscal year 2023.

Key Points:

LENEXA, Kansas, April 02, 2024 (GLOBE NEWSWIRE) -- Digital Ally, Inc. (Nasdaq: DGLY) (the “Company” or “our”), today announced its operating results for fiscal year 2023.
Operating losses for the year ended December 31, 2023 and 2022 were $22,240,553 and $29,733,258, respectively, a decrease of $7,492,705 (25%).
Operating loss as a percentage of revenues improved to 78% in 2023 from 80% in 2022.
The Company will host an investor conference call at 11:15 a.m. EDT on Tuesday, April 2, 2023, to discuss its 2023 financial results, corporate and individual subsidiary outlook, and previously announced corporate separation.

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

Retrieved on:

Tuesday, April 2, 2024

BofA Securities, SAN, Research, Sale, STRO, Public expenditure, Attention, Security (finance), Spacecraft, Prospectus, Investment

SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 14,478,764 shares of its common stock at a price of $5.18 per share.

Key Points:

SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 14,478,764 shares of its common stock at a price of $5.18 per share.
The gross proceeds from this offering are expected to be approximately $75.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro.
All of the shares of common stock are being offered by Sutro.
The offering is expected to close on or about April 4, 2024, subject to the satisfaction of customary closing conditions.

Zhibao Technology Inc. Announces Pricing of Initial Public Offering

Retrieved on:

Tuesday, April 2, 2024

Fintech, Madison Avenue, EF Hutton, Offering, Form, Telephone, Sale, Attention, Security (finance), Prospectus, File

The offering is expected to close on April 3, 2024, subject to customary closing conditions.

Key Points:

The offering is expected to close on April 3, 2024, subject to customary closing conditions.
EF Hutton LLC is acting as the sole book-running manager for the Offering.
The Offering is being made only by means of a prospectus, forming part of the effective registration statement.
In addition, a copy of the final prospectus, when available, relating to the Offering may be obtained via the SEC's website at www.sec.gov .

VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on:

Tuesday, April 2, 2024

Psoriasis, Defendant, News, IPO, Inflammation, Plaque, Prospectus, Complaint, Court, Person, Pharmaceutical industry

Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.

Key Points:

Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.
The Company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.
On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Applied UV, Inc. Announces Closing of $2.76 Million Registered Direct and Private Placement

Retrieved on:

Monday, April 1, 2024

Common stock, Private, Exercise, Form, Telephone, Common, Sale, Attention, Share (finance), Form S-3, Prospectus, P.C, Security (finance)

The Company issued shares of common stock of the Company (“Common Stock”) and pre-funded warrants (“Pre-Funded Warrants”) in a registered direct offering.

Key Points:

The Company issued shares of common stock of the Company (“Common Stock”) and pre-funded warrants (“Pre-Funded Warrants”) in a registered direct offering.
In a concurrent private placement, the Company also issued common warrants (“Common Warrants”) to the same investors.
Aggregate gross proceeds to the Company from both transactions were approximately $2.76 million.
The registered direct offering was being made pursuant to an effective shelf registration statement on Form S-3 (No.

U-BX Technology Ltd. Announces Closing of $10 Million Initial Public Offering

Retrieved on:

Monday, April 1, 2024

EF Hutton, Common stock, Madison Avenue, Offering, Form, Telephone, Winston & Strawn, Sale, Insurance, Prospectus, ATTN:, Security (finance)

Beijing, April 01, 2024 (GLOBE NEWSWIRE) -- U-BX Technology Ltd. (the “Company” or “UBXG”), an artificial intelligence-driven value-added services and products provider to insurance carriers, today announced the closing of its initial public offering (the "Offering") of 2,000,000 ordinary shares (the "Ordinary Shares") at an initial public offering price of $5.00 per share for total gross proceeds of $10,000,000, before deducting underwriting discounts and other offering expenses.

Key Points:

Beijing, April 01, 2024 (GLOBE NEWSWIRE) -- U-BX Technology Ltd. (the “Company” or “UBXG”), an artificial intelligence-driven value-added services and products provider to insurance carriers, today announced the closing of its initial public offering (the "Offering") of 2,000,000 ordinary shares (the "Ordinary Shares") at an initial public offering price of $5.00 per share for total gross proceeds of $10,000,000, before deducting underwriting discounts and other offering expenses.
The Offering closed on April 1, 2024, and the Ordinary Shares began trading on Nasdaq Capital Market on March 28, 2024, under the ticker symbol "UBXG".
The Company has granted EF Hutton LLC (“EF Hutton”), the underwriter, an option to purchase up to an additional 300,000 Ordinary Shares at the public offering price, less underwriting discounts, to cover the over-allotments, if any, exercisable within 45 days from the closing date of the Offering.
EF Hutton acted as the sole bookrunner for the Offering.

Innovator Expands Defined Protection 100% Buffer ETF™ Suite with AAPR Following Market Demand

Retrieved on:

Monday, April 1, 2024

Option, Funding, ETF, Name, Risk, FLEX, Date, Lovell Minnick Partners, Distribution, Prospectus, Investment, OCC, Fund, Security (finance)

The funds only seek to provide their investment objective, which is not guaranteed, over the course of an entire outcome period.

Key Points:

The funds only seek to provide their investment objective, which is not guaranteed, over the course of an entire outcome period.
Depending upon market conditions at the time of purchase, a shareholder that purchases shares after the Outcome Period has begun may also lose their entire investment.
For instance, if the Outcome Period has begun and the Fund has decreased in value beyond the pre-determined buffer, an investor purchasing shares at that price may not benefit from the buffer.
The Funds seek to provide shareholders that hold Shares for the entire Outcome Period with a Buffer against the Underlying ETF losses during the Outcome Period.

Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on:

Monday, April 1, 2024

3rd Floor, Exercise, Form, SAN, Sale, Security (finance), Prospectus, Investment, Therapy, Regulation D

(Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 5,454,548 shares of the Company’s common stock at an offering price of $1.10 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.

Key Points:

(Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 5,454,548 shares of the Company’s common stock at an offering price of $1.10 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.
In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 5,454,548 shares of common stock.
The closing of the offering is expected to occur on or about April 3, 2024, subject to the satisfaction of customary closing conditions.
The gross proceeds to Biora from this offering are expected to be approximately $6 million, before deducting the placement agent’s fees and other offering expenses.

Dividend 15 Split Corp. At-The-Market Equity Program Renewed

Retrieved on:

Monday, April 1, 2024

TORONTO, April 01, 2024 (GLOBE NEWSWIRE) -- Dividend 15 Split Corp. (the “Company”) announces it has renewed its at-the-market equity program (“ATM Program”) that allows the Company to issue shares of the Company to the public from time to time at the Company’s discretion, effective until September 9, 2024, unless terminated prior to such date by the Company.

Key Points:

TORONTO, April 01, 2024 (GLOBE NEWSWIRE) -- Dividend 15 Split Corp. (the “Company”) announces it has renewed its at-the-market equity program (“ATM Program”) that allows the Company to issue shares of the Company to the public from time to time at the Company’s discretion, effective until September 9, 2024, unless terminated prior to such date by the Company.
This ATM Program replaces the prior program established in August 2022 that has terminated.
Sales of Class A Shares and Preferred Shares through the ATM Program will be made pursuant to the terms of an equity distribution agreement dated March 28, 2024 with National Bank Financial Inc. (the “Agent”).
The volume and timing of distributions under the ATM Program, if any, will be determined at the Company’s sole discretion.